AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development (Antivirals)
"Kinetics of Antiviral Activity by HIV Type I-Specific Cytotoxic T Lymphocytes and Rapid Selection of CTL Escape Virus in vitro."
August 23rd, 1999
According to an abstract submitted by the authors to the Fourth European Conference on Experimental AIDS Research, held June 18-21, 1999 in Tampere, Finland, "The antiviral activity of a CD8+ cytotoxic T-lymphocyte (CTL) clone (TCC108) directed against a newly identified HLA-B14/Cw8 restricted epitope, HIV-1 Rev(67-75) SAEPVPLQL, was analyzed with respect to its kinetics of target cell lysis and inhibition of HIV-1 production. Addition of TCC108 or CD8+ reverse transcriptase (RT)-specific CTL to HLA-matched CD4+ T cells at different times after infection with HIV-1 IIIB showed that infected cells became susceptible to CTL-mediated lysis before peak virus...
Source: AIDS Weekly (1999-08-23)
|
|
Advertisement |
|
|
